Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

1672745

USP

Tranexamic acid

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

trans-4-(Aminomethyl)cyclohexanecarboxylic acid, AMCA, AMCHA, HAKU, TAMCHA, Tranexamic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
H2NCH2C6H10CO2H
Numéro CAS:
1197-18-8
Poids moléculaire :
157.21
Beilstein:
2207452
Numéro MDL:
MFCD00001466
Code UNSPSC :
41116107
ID de substance PubChem :
329751362
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

tranexamic acid

Fabricant/nom de marque

USP

Pf

>300 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI

1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

Clé InChI

GYDJEQRTZSCIOI-LJGSYFOKSA-N

Informations sur le gène

human ... PLG(5340)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Tranexamic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Tranexamic Acid Tablets
  • Tranexamic Acid Injection

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H315,H319,H335

Classification des risques

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

Fibrinogène from human plasma 50-70% protein (≥80% of protein is clottable)

Sigma-Aldrich

F3879

Fibrinogène from human plasma

Kit de prolifération cellulaire II (XTT) liquid, pkg of 1 kit, suitable for cell analysis, suitable for tissue culture

Roche

11465015001

Kit de prolifération cellulaire II (XTT)

Pluronic® F-127 powder, BioReagent, suitable for cell culture

Sigma-Aldrich

P2443

Pluronic® F-127

V Pundir et al.
Rhinology, 51(4), 291-297 (2013-11-22)
The role of tranexamic acid in patients undergoing endoscopic sinus surgery (ESS) is not clearly defined. The aim of our study is to systematically review the existing evidence on the role of tranexamic acid in patients undergoing ESS. Systematic search
Anthony E Pusateri et al.
Shock (Augusta, Ga.), 39(2), 121-126 (2012-12-12)
A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies
Baohui Yang et al.
PloS one, 8(2), e55436-e55436 (2013-02-21)
Tranexamic acid (TXA) is well-established as a versatile oral, intramuscular, and intravenous (IV) antifibrinolytic agent. However, the efficacy of IV TXA in reducing perioperative blood transfusion in spinal surgery is poorly documented. We conducted a meta-analysis of randomized controlled trials
Zhi-Jun Li et al.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 22(9), 1950-1957 (2013-05-10)
The present meta-analysis aimed at assessing the effectiveness and safety of tranexamic acid (TXA) in reducing blood loss and transfusion in spinal surgery. Systematic searches of all studies published through March 2012 were identified from PubMed, EMBase, Cochrane library, Science
Chih-Hsiang Chang et al.
Clinical orthopaedics and related research, 472(5), 1552-1557 (2014-01-05)
Systemic tranexamic acid can decrease blood loss and rates of transfusion in patients undergoing total hip arthroplasty (THA). However, the efficacy of topical tranexamic acid in THA has only recently been characterized in a small number of studies. The purpose
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique